Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05248594 · ClinicalTrials.gov registry record
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
A clinical trial, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- 71
- Enrollment target
NCT05248594 is a clinical trial that has completed, run by Montefiore Medical Center. The registered enrollment target is 71 participants.
The verdict
NCT05248594 has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
Hemophilia A (HA) is a rare congenital bleeding disorder characterized by coagulation factor VIII deficiency. In severe HA, defined as plasma FVIII clotting activity \< 1%, bleeding may frequently occur spontaneously, most commonly in joints, leading to painful hemophilic arthropathy and loss of joint function. Patients with moderate or mild hemophilia A, defined as FVIII clotting activity between 1-\<5% and 5-40% respectively, are less likely to have spontaneous bleeding however can have significant bleeding with trauma or surgery. Perioperative management by a hematologist who specializes in hemophilia is needed to ensure hemostasis during surgery. Hemophilia is an X-linked recessive disorder affecting 1 in 5000 to 10,000 males.
Interventions
- DRUG HEMLIBRA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2025-07-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05248594
The ClinicalTrials.gov registry entry for NCT05248594 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HEMLIBRA is the first listed.
NCT05248594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05248594 about?
NCT05248594 is a clinical study titled "Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A". Hemophilia A (HA) is a rare congenital bleeding disorder characterized by coagulation factor VIII deficiency. In severe HA, defined as plasma FVIII clotting activity \< 1%, bleeding may frequently occur spontaneously, most commonly in joints, leading to painful hemophilic arthropathy and loss of joi...
What is the current status of trial NCT05248594?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2024-08-01. Estimated completion is 2025-07-18.
What interventions are being tested in trial NCT05248594?
The interventions under investigation include: HEMLIBRA (DRUG).
Who is sponsoring clinical trial NCT05248594?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.